Metabolic Biomarker Testing Market Report 2026

Metabolic Biomarker Testing Market Overview

• Metabolic Biomarker Testing market size has reached to $3.06 billion in 2025 • Expected to grow to $4.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Surge In Diabetic Patients Fuels Growth In Metabolic Biomarker Testing Market • Market Trend: Innovative Diagnostics Platform Delivers Multi-Indicator Results In Minutes • North America was the largest region in 2025.

What Is Covered Under Metabolic Biomarker Testing Market?

Metabolic biomarker testing refers to the analysis of specific molecules in biological samples, such as blood or urine, to assess metabolic processes and identify imbalances or dysfunctions. This testing helps in diagnosing metabolic disorders, monitoring health conditions, and guiding personalized treatment strategies. The main types of metabolic biomarker testing are separation techniques, detection techniques, and others. Separation techniques involve methods that use physical or chemical processes to separate specific metabolites from a biological sample based on their physical properties, such as size, charge, or affinity, which help in purifying and identifying metabolic biomarkers and deliver high precision in identifying metabolites. The indication types include cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others, and applications are categorized into drug assessment, nutrigenomics, toxicology testing, personalized medicine, functional genomics, and others. The end users include pharmaceutical and biotech companies, diagnostic tool companies, healthcare information technology (IT), and clinical laboratories.

What Is The Metabolic Biomarker Testing Market Growth Forecast?

The metabolic biomarker testing market size is expected to see strong growth in the next few years. It will grow to $4.54 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing demand for personalized healthcare solutions, rising investments in precision diagnostics, expansion of preventive health screening programs, growing use of ai-driven data interpretation, increasing collaboration between diagnostics and pharmaceutical companies. Major trends in the forecast period include increasing adoption of metabolomics-based diagnostics, rising use of biomarkers in personalized medicine, growing integration of advanced analytical techniques, expansion of early disease detection applications, enhanced focus on data-driven clinical decision making.

Global Metabolic Biomarker Testing Market Segmentation

1) By Type: Separation Techniques, Detection Techniques, Other Types 2) By Indication: Cancer, Cardiovascular Disorders, Neurological Disorders, Inborn Errors Of Metabolism, Other Indications 3) By Application: Drug Assessment, Nutrigenomics, Toxicology Testing, Personalized Medicine, Other Applications 4) By End User: Pharma And Biotech Companies, Diagnostic Tool Companies, Clinical Laboratories Subsegments: 1) By Separation Techniques: Chromatography, Capillary Electrophoresis, Mass Spectrometry (MS), Liquid-Liquid Extraction, Solid-Phase Extraction 2) By Detection Techniques: Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence-Based Detection, Electrochemical Detection, Nuclear Magnetic Resonance (NMR), Immunoassays 3) By Other Types: Metabolomics Profiling, Spectroscopy Techniques

What Is The Driver Of The Metabolic Biomarker Testing Market?

The rising incidence of diabetes is expected to propel the growth of the metabolic biomarker testing market going forward. Diabetes is a chronic medical condition characterized by high blood glucose levels due to the body's inability to produce or effectively use insulin. The rise in diabetes is driven by a poor diet, especially high consumption of processed foods and sugary drinks, and sedentary lifestyles characterized by minimal physical activity. Moreover, the aging population and family history of diabetes increase the risk, indicating a genetic predisposition. Metabolic biomarker testing helps in diagnosing, monitoring, and managing metabolic illnesses such as diabetes by providing insights into metabolic functions and abnormalities at a molecular level. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium based diabetes advocacy organization, the number of adults (age 20–79 years) living with diabetes worldwide reached 589 million, a sharp rise from prior years. and the total number of adults with diabetes is predicted to rise to 853 million by 2050. Therefore, the rising incidence of diabetes will drive the growth of the metabolic biomarker testing industry.

Key Players In The Global Metabolic Biomarker Testing Market

Major companies operating in the metabolic biomarker testing market are Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., PerkinElmer Inc., bioMérieux S.A., LECO Corporation, Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, SCIEX, Promega Corporation, Cayman Chemical Company, Metabolon Inc., Biocrates Life Sciences AG, Human Metabolome Technologies Inc., KineMed Inc., Evosep Biosystems A/S, Creative Proteomics Inc., Lipotype GmbH, Metabolomic Diagnostics Ltd, Stemina Biomarker Discovery Inc., Chenomx Inc., GlycoPath Pty Ltd

Global Metabolic Biomarker Testing Market Trends and Insights

Major companies operating in the metabolic biomarker testing market are focusing on developing innovative solutions, such as lab-quality home blood testing platforms, to meet the rising demand for convenient, accurate, and timely metabolic health monitoring. Lab-quality home blood testing platforms are compact, user-friendly devices designed for at-home use that provide results comparable to traditional laboratory tests. For instance, in January 2023, SiPhox Health, Inc., a U.S.-based health technology company, launched the world's first lab-quality home blood testing platform, offering users the ability to monitor multiple metabolic biomarkers from the comfort of their homes. The platform incorporates proprietary technology to ensure high accuracy, provides real-time results through a connected app, and supports a wide range of metabolic health assessments, including glucose, lipid profiles, and other key indicators. Its unique combination of lab-grade precision and at-home accessibility enables more frequent monitoring, early detection of metabolic disorders, and personalized health management.

What Are Latest Mergers And Acquisitions In The Metabolic Biomarker Testing Market?

In June 2024, Lifesum AB, a Sweden-based provider of a healthy eating and wellness platform, acquired Lykon GmbH for an undisclosed amount. The acquisition aims to integrate Lykon's biomarker testing into Lifesum's platform to offer personalized health insights, expand wellness services, and strengthen Lifesum's position in the advanced wellness market. Lykon GmbH is a Germany-based company specializing in personalized metabolic and nutritional testing.

Regional Outlook

North America was the largest region in the metabolic biomarker testing market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Metabolic Biomarker Testing Market?

The metabolic biomarker testing market consists of revenues earned by entities by providing services such as laboratory testing, analysis of blood, urine, and other biological samples, and personalized health assessments. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic biomarker testing market also includes sales of diagnostic kits, assay reagents, and testing equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Metabolic Biomarker Testing Market Report 2026?

The metabolic biomarker testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic biomarker testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.